Viltepso
Named-patient access overview. Viltepso is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Viltepso (viltolarsen) is an antisense oligonucleotide that promotes skipping of exon 53 in the dystrophin pre-mRNA, restoring partial dystrophin production in Duchenne muscular dystrophy (DMD) patients with deletions amenable to exon 53 skipping. The US Food and Drug Administration granted accelerated approval to viltolarsen in August 2020 for DMD in patients who have a confirmed mutation of the DMD gene amenable to exon 53 skipping. Viltepso is approximately manufactured and commercialised by NS Pharma, a subsidiary of Nippon Shinyaku of Japan.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Viltepso
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Viltepso is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Viltepso in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Viltepso
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.